Cost-effectiveness and cost-utility analysis
Compare the extra cost of a strategy with the extra health it produces, using a shared perspective and time horizon.
Why this level?
not one of the five research areas this hierarchy covers. NHMRC 2009 sourceEconomic value is not one of the five research areas this hierarchy covers. The evidence label is not a judgment on the quality of the evaluation.
Fit
When to use it, and when not to
Use it when
- You need to judge health gained for the resources spent.
- You can estimate costs and health outcomes for relevant alternatives.
Not when
- You need next year's cash requirement. Use a budget impact analysis.
- You only need a treatment effect. Use a randomized trial when feasible. Read: Randomized controlled trial
Before you start
What you need
- The decision, population and comparatorsInclude the care that would otherwise be used.
- Whose costs countA health service and society can count different costs. State currency and price year.
- The time horizon and discount rulesUse a horizon that captures important differences. Discount future costs and health as local guidance requires.
- The health outcomeDefine natural health units or quality-adjusted life-years. One such year combines time alive with a health-state value.
- Inputs and their uncertaintyState evidence sources, model assumptions, missingness assumptions and plausible alternative scenarios.
- Health effects are credible for the target population.How to check: Appraise their study design and whether results transfer to the decision setting.
- Costs and health cover the same comparison and horizon.How to check: Check the model against the decision and avoid mixing perspectives.
- The decision reflects uncertainty in costs and effects.How to check: Vary key assumptions and jointly sample uncertain inputs with their dependencies.
Plain language
How it works
Estimate costs and health under each strategy. Subtract the comparator totals to get incremental cost and health, meaning the extra amounts. Divide extra cost by extra health when that ratio has a useful interpretation.
Cost-utility analysis is this framework with health in quality-adjusted life-years. It does not value health in money. Assess uncertainty and whether another strategy costs less and works better. Report what changes when assumptions or the decision threshold change. Use CHEERS 2022 to report the decision, inputs, uncertainty and economic results.
Worked example
A worked example
- Setting
- A service compares two care strategies over the same horizon.
- Question
- Is the added health worth the extra cost?
- Approach
- Use a health-service perspective. Both cost and health figures are invented totals per person.
- Result
- Costs rise from $1000 to $1200, an extra $200. Health rises from 4.0 to 4.1 quality-adjusted life-years. The ratio is $2000 per added quality-adjusted life-year.
- What it means
- Compare this ratio with the decision maker's value threshold and uncertainty. The ratio alone does not show affordability.
In practice
Recent studies PubMed search · not vetted
Watch out
Common mistakes
The one to remember
Value depends on the comparator, perspective, time horizon and health measure. A cost-effective option may still be unaffordable, and a ratio alone hides uncertainty.
- Comparing average cost per outcome within each strategy.Instead: Compare the differences between strategies. Check for options that cost more and deliver less health.
- Reporting only a ratio.Instead: Show differences in cost and health, uncertainty, and the decision threshold. A near-zero health difference can make the ratio unstable.
Inside Mallard
How Mallard uses this
Plans do not link to this design yet. Mallard has no dedicated sizing form for cost-effectiveness and cost-utility analysis.
design.cost_effectiveness_utility, the id a plan cue records.Related Learn pages
Related designs and methods
Evidence
Sources & further reading
- The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS (opens in a new tab) · Diabetes Care · doi 10.2337/dc11-1468
- Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States (opens in a new tab) · Ann Intern Med · doi 10.7326/M14-1336
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations (opens in a new tab) · Value Health · doi 10.1016/j.jval.2021.11.1351